Analysis of the Role of Igf2 in Adrenal Tumour Development in Transgenic Mouse Models
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Adrenal cortical carcinomas (ACC) are rare but aggressive tumours associated with poor prognosis. The two most frequent alterations in ACC in patients are overexpression of the growth factor IGF2 and constitutive activation of Wnt/β-catenin signalling. Using a transgenic mouse model, we have previously shown that constitutive active β-catenin is a bona fide adrenal oncogene. However, although all these mice developed benign adrenal hyperplasia, malignant progression was infrequent, suggesting that secondary genetic events were required for aggressive tumour development. In the present paper, we have tested IGF2 oncogenic properties by developing two distinct transgenic mouse models of Igf2 overexpression in the adrenal cortex. Our analysis shows that despite overexpression levels ranging from 7 (basal) to 87 (ACTH-induced) fold, Igf2 has no tumour initiating potential in the adrenal cortex. However, it induces aberrant accumulation of Gli1 and Pod1-positive progenitor cells, in a hedgehog-independent manner. We have also tested the hypothesis that Igf2 may cooperate with Wnt signalling by mating Igf2 overexpressing lines with mice that express constitutive active β-catenin in the adrenal cortex. We show that the combination of both alterations has no effect on tumour phenotype at stages when β-catenin-induced tumours are benign. However, there is a mild promoting effect at later stages, characterised by increased Weiss score and proliferation. Formation of malignant tumours is nonetheless a rare event, even when Igf2 expression is further increased by ACTH treatment. Altogether these experiments suggest that the growth factor IGF2 is a mild contributor to malignant adrenocortical tumourigenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Erk Associates with and Primes GSK-3β for Its Inactivation Resulting in Upregulation of β-Catenin
Ding, Q., Xia, W., Liu, J.-C., Yang, J.-Y., Lee, D.-F., Xia, J., Bartholomeusz, G., Li, Y., Pan, Y., Li, Z., et al. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.06.009 · Cited by 597 · cited 2×
“This crosstalk was assumed to play a role in the potential oncogenic effects of Igf2 [33–37].”
BackgroundIcard, P., Goudet, P., Charpenay, C., Andreassian, B., Carnaille, B., Chapuis, Y., Cougard, P., Henry, J., & Proye, C. (2001) · World Journal of Surgery · doi:10.1007/s00268-001-0047-y · Cited by 543
Tissier, F., Cavard, C., Groussin, L., Perlemoine, K., Fumey, G., Hagneré, A.-M., René-Corail, F., Jullian, E., Gicquel, C., Bertagna, X., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0593 · Cited by 474 · cited 1×
“ACC are overexpression of Igf2 [8–10] and constitutive activation of the Wnt/b-catenin signalling pathway [11–13].”
BackgroundSelf-citationAbiven, G., Coste, J., Groussin, L., Anract, P., Tissier, F., Legmann, P., Dousset, B., Bertagna, X., & Bertherat, J. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2730 · Cited by 435
Self-citationDistinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis
Giordano, T. J., Thomas, D. G., Kuick, R., Lizyness, M., Misek, D. E., Smith, A. L., Sanders, D., Aljundi, R. T., Gauger, P. G., Thompson, N. W., et al. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63846-1 · Cited by 383 · cited 7×
“Regulatory regions from the human P450SSC gene (24400/+55) were amplified from human genomic DNA using primers SCC-Fwd-59-GCTCTAGAGCGACCCCTCCCAAGGCCAAACAAA-39 and SCC-Rev59-CCCTCGAGGGCCCACAGCTGTGACTGTAC-39.”
BackgroundInfluentialde Reyniès, A., Assié, G., Rickman, D. S., Tissier, F., Groussin, L., René-Corail, F., Dousset, B., Bertagna, X., Clauser, E., & Bertherat, J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.5678 · Cited by 382
Self-citationde Fraipont, F., El Atifi, M., Cherradi, N., Le Moigne, G., Defaye, G., Houlgatte, R., Bertherat, J., Bertagna, X., Plouin, P.-F., Baudin, E., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1075 · Cited by 261
Self-citationPrognostic parameters of metastatic adrenocortical carcinoma
Assié, G., Antoni, G., Tissier, F., Caillou, B., Abiven, G., Gicquel, C., Leboulleux, S., Travagli, J.-P., Dromain, C., Bertagna, X., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0706 · Cited by 236 · cited 1×
“are also associated with excessive hormone secretion [3,4].”
BackgroundSelf-citationDoghman, M., Wakil, A. E., Cardinaud, B., Thomas, E., Wang, J., Zhao, W., Peralta-Del Valle, M. H. C., Figueiredo, B. C., Zambetti, G. P., & Lalli, E. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3970 · Cited by 221 · cited 1×
“This seems particularly relevant in light of the recent finding that mTOR pathway is activated and involved in growth stimulation of paediatric adrenocortical carcinomas [49], tumour entities that are also associated with IGF2 overexpression [20].”
BackgroundPreclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma
Barlaskar, F. M., Spalding, A. C., Heaton, J. H., Kuick, R., Kim, A. C., Thomas, D. G., Giordano, T. J., Ben-Josef, E., & Hammer, G. D. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1456 · Cited by 189
Cited by
Else, T., Kim, A. C., Sabolch, A., Raymond, V. M., Kandathil, A., Caoili, E. M., Jolly, S., Miller, B. S., Giordano, T. J., & Hammer, G. D. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1029 · Cited by 892
Update in Adrenocortical Carcinoma
Fassnacht, M., Kroiss, M., & Allolio, B. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3020 · Cited by 414
PKA inhibits WNT signalling in adrenal cortex zonation and prevents malignant tumour development
Drelon, C., Berthon, A., Sahut-Barnola, I., Mathieu, M., Dumontet, T., Rodriguez, S., Batisse-Lignier, M., Tabbal, H., Tauveron, I., Lefrançois-Martinez, A.-M., et al. (2016) · Nature Communications · doi:10.1038/ncomms12751 · Cited by 128
Self-citationAdrenocortical zonation, renewal, and remodeling
Pihlajoki, M., Dörner, J., Cochran, R. S., Heikinheimo, M., & Wilson, D. B. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00027 · Cited by 114
“Constitutive activation of β-catenin signaling in the mouse zF using Akr1b7-cre triggers the ectopic expression of the zG marker Cyp11b2 and increased production of aldosterone (40, 65).”
Adrenocortical cancer and IGF2: is the game over or our experimental models limited?
Drelon, C., Berthon, A., & Val, P. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3310 · Cited by 24
Self-citation
Metadata
- Authors
- Drelon, C., Berthon, A., Ragazzon, B., Tissier, F., Bandiera, R., Sahut-Barnola, I., de Joussineau, C., Batisse-Lignier, M., Lefrançois-Martinez, A.-M., Bertherat, J., Martinez, A., & Val, P.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-08-28
- Volume
- 7
- Issue
- 8
- Pages
- e44171
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2015366457
- Cited by
- 81
- References
- 13
- FWCI
- 9.92
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Analysis of the Role of Igf2 in Adrenal Tumour Development in Transgenic Mouse Models. https://app.cochat.ai/papers/10.1371/journal.pone.0044171
- The paper
- Drelon, C., Berthon, A., Ragazzon, B., Tissier, F., Bandiera, R., Sahut-Barnola, I., de Joussineau, C., Batisse-Lignier, M., Lefrançois-Martinez, A.-M., Bertherat, J., Martinez, A., & Val, P. (2012). Analysis of the Role of Igf2 in Adrenal Tumour Development in Transgenic Mouse Models. PLoS ONE. https://doi.org/10.1371/journal.pone.0044171
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.